Shares of Pfizer fell 4.85% to $39.12 at 16:12 EST on Monday, after three successive sessions in a row of losses. The New York Stock Exchange is dropping 0.49% to $14,284.40, following yesterday’s downward trend, This seems, so far, a somewhat rough trend exchanging session today.
Pfizer’s last close was $41.12, 10.12% under its 52-week high of $43.08.
News about Pfizer today
Pfizer May offer shots to trial volunteers who received placebo. According to today’s article on Bloomberg Quint, “Pfizer Inc. and BioNTech SE may soon allow participants in its Covid-19 vaccine trial to learn whether they received a placebo, rather than the real thing, and get the actual shot if they wish.”, “”Pending required approvals, Pfizer and BioNTech plan to provide an option for clinical trial participants who received the placebo to get the vaccine at scheduled time points in the study,” Pfizer said in an emailed statement. ”
US covid-19 vaccinations to begin Monday as CDC recommends Pfizer vaccine. According to today’s article on Business Insider, “The United States is likely to start Covid-19 vaccinations on Monday after Robert Redfield, the director of the Centers for Disease Control and Prevention or CDC, gave the approval for Pfizer- BioNTech’s COVID-19 vaccine, multiple reports said.”, “According to Perna, it is expected that 145 sites across all the states will receive vaccine on Monday, another 425 sites on Tuesday, and the final 66 sites on Wednesday in the initial delivery of the Pfizer orders for vaccine.”
Pfizer, biontech covid-19 vaccine candidate study in Germany support safety profile. According to today’s article on MarketWatch, “Pfizer Inc. and its Germany-based partner BioNTech SE said overall results of a Phase 1/2 study in Germany of its COVID-19 vaccine candidate, BNT162b2, mirrored those from the U.S. study. “, “The study’s result come as the companies’ vaccine is being distributed for use in the U.S. Shares of Pfizer rose 1.5% in premarket trading and BioNTech’s stock gained 0.9%, as futures for the S&P 500 tacked on 0.6%.”
Pfizer, biontech report data from german phase 1/2 trial with covid-19 vaccine candidate. According to today’s article on Business Insider, “Pfizer Inc. (PFE) and BioNTech SE (BNTX) reported additional data on neutralizing antibody and T cell responses from the phase 1/2 trial with BNT162b2 conducted in Germany. “, “BNT162b2 is an investigational COVID-19 vaccine developed by Pfizer-BioNTech. ”
Pfizer’s sales growth is a negative 9.7% for the current quarter and a decline by 0.5% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 9.1% and a negative 8.8%, respectively.
Year-on-year quarterly revenue growth declined by 4.3%, now sitting on 48.65B for the twelve trailing months.
Pfizer’s Stock Top and Bottom Yearly Value
Pfizer’s stock is valued at $39.12 at 16:12 EST, below its 52-week high of $43.08 and way higher than its 52-week low of $26.45.
Pfizer’s Moving Average
Pfizer’s value is higher than its 50-day moving average of $37.15 and way higher than its 200-day moving average of $35.17.
Previous days news about Pfizer
Netanyahu will be first to get Pfizer vaccine in Israel. According to Bloomberg Quint on Wed Dec 9, “Israeli Prime Minister Benjamin Netanyahu said he’s going to demonstrate his faith in Pfizer Inc.’s coronavirus vaccine by being the first in the country to be inoculated.”
U.k. says those with severe allergy shouldn’t get Pfizer jab. According to Bloomberg Quint on Wed Dec 9, “People with a significant history of allergies should not currently receive the Covid-19 vaccine from Pfizer Inc. and BioNTech SE, the U.K.’s National Health Service said, after two people experienced reactions from the shots.”, “Pfizer and BioNTech said they’re supporting the MHRA in its investigation.”
Head of FDA advisory panel predicts approval for Pfizer vaccine. According to The Wall Street Journal on Wed Dec 9, “”We’re not at the borderline on efficacy,” he added, referring to data from the vaccine’s makers- Pfizer Inc. and Germany’s BioNTech SE-showing the shot is 95% effective at protecting against Covid-19, significantly higher than the 50% minimum the FDA had said would be required for an emergency authorization.”, “The committee has been reviewing the data from Pfizer’s trial since last week.”
Canada approves Pfizer vaccine with first batch due next week. According to Bloomberg Quint on Wed Dec 9, “That will depend on approval of other vaccines; the country of 38 million people has secured 20 million doses of the Pfizer-BioNTech shot.”, “Canada expects to begin receiving next week the first of a batch of 249,000 Pfizer-BioNTech doses, with the order filled partly from facilities in Belgium. ”
Pfizer says some vaccine documents accessed in EMA cyberattack. According to Bloomberg Quint on Wed Dec 9, “Pfizer and BioNTech said the EMA informed them that the attack would have no effect on the timing of the vaccine review. “, “Pfizer shares closed on Wednesday down 1.7% to $41.85 in New York.”
First u.s. shipments of Pfizer vaccine will be 2.9 million doses. According to Bloomberg Quint on Wed Dec 9, “In late November they were told 6.4 million doses of Pfizer’s vaccine candidate would be available at first, and 12.5 million of Moderna Inc.’s shot after it is authorized.”, “Less than half of the available 6.4 million doses of Pfizer Inc.’s Covid-19 vaccine will be initially sent out to states, and 500,000 will be held separately in reserve by the government, according to a top official at Operation Warp Speed.”
Pfizer shot gets FDA advisers’ nod as agency decision nears. According to Bloomberg Quint on Thu Dec 10, “The U.K. approved Pfizer’s shot earlier this month, but said people with a significant history of allergies should not take it after two people suffered reactions. “, “Pfizer shares rose 2.4% in trading after the market close in New York. ”
Moderna offers u.s. fail-safe on vaccines if Pfizer falls short. According to Bloomberg Quint on Thu Dec 10, “Moderna Inc. could offer a fail-safe option that will allow the U.S. to get enough Covid-19 shots to inoculate most Americans if the government can’t reach an agreement to quickly buy more vaccine from Pfizer Inc., which plans to honor its contracts with other countries.”, “On Tuesday, a Pfizer board member said that the U.S. government been offered 100 million more doses that could be delivered in the spring, but declined. ”
FDA nears Pfizer decision; Australia cancels order: virus update. According to Bloomberg Quint on Fri Dec 11, “A New York state panel of public-health advisers approved a Food and Drug Administration committee’s backing for emergency use authorization of the Pfizer Inc. and BioNTech SE vaccine, Governor Andrew Cuomo said on Twitter.”, “The FDA intends to proceed toward emergency use authorization of the Pfizer-BioNTech vaccine, he said.”
Pfizer vaccine clearance to be sought in Hong Kong after FDA nod. According to Bloomberg Quint on Fri Dec 11, “Fosun has yet to apply for authorization for the Pfizer-BioNTech vaccine’s use in mainland China. “, “Authorization for the Pfizer-BioNTech shot in the Asian financial hub would be among a wave of rubber-stamp approvals expected around the world, as many endorsements are contingent on the U.S. Food and Drug Administration approving the vaccine, which could come as soon as this weekend. ”
Pfizer raises quarterly cash dividend to 39 cents a share vs. 38 cents. According to MarketWatch on Fri Dec 11, “Pfizer Inc. said Friday’s its board has raised its quarterly cash dividend to 39 cents a share from 38 cents in the year-earlier period. “, “”It is expected that Viatris will begin paying a quarterly dividend in the second quarter of 2021, at which time Pfizer’s quarterly dividend will be reduced such that the combined dividend dollar amount received by Pfizer shareholders, based upon the combination of continued Pfizer ownership and approximately 0.124079 shares of Viatris which were granted for each Pfizer share in the spin-off, will equate to Pfizer’s dividend amount in effect immediately prior to the initiation of the Viatris dividend,” the company said in a statement. ”
FDA aiming for quick authorization of Pfizer covid vaccine. According to Bloomberg Quint on Fri Dec 11, “”That’s something we’re working with Pfizer right now on is the appropriate language for the doctors, is if you have a pre-existing serious allergic reaction to anything in these vaccines or medical allergies, you should exercise caution in getting these vaccines initially,” Azar said on Friday in an interview with Fox Business News.”, “Azar tweeted that Pfizer has already been advised that the authorization was coming.”
Pfizer vaccine cleared in u.s., a landmark in covid-19 fight. According to Bloomberg Quint on Sat Dec 12, “A shot similar to Pfizer and BioNTech’s made by Moderna Inc. is expected to gain U.S. clearance next week, providing the country with a potent combination for beating back the pathogen. “, “Pfizer has developed special dry-ice containers to make it easier to store for facilities that don’t have the needed equipment.”
Mexico approves Pfizer vaccine for emergency use as covid surges. According to Bloomberg Quint on Sat Dec 12, “Mexico’s health agency Cofepris approved Pfizer’s coronavirus vaccine for emergency use, Deputy Health Minister Hugo Lopez-Gatell said at a press conference Friday night.”, “Mexico joins the U.K., Canada and the U.S. as countries that have granted emergency use of the Pfizer vaccine. ”
Pfizer says prepared to deliver first doses of covid-19 vaccine in u.s. immediately. According to Business Insider on Sat Dec 12, “Pfizer will have marketing and distribution rights worldwide with the exception of China, Germany, and Turkey.”, “Pfizer and BioNTech said that they are confident in their ability to deliver the vaccine to people in the U.S. Their combined manufacturing network has the potential to supply globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021.”
U.s. CDC committee of independent health experts recommends vaccination with Pfizer and biontech covid-19 vaccine for persons ages 16 years and older. According to Business Insider on Sat Dec 12, “A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.”